News / Taiwan / cnyes
Huaan Plans $300 Million Capital Raise to Accelerate Drug Trials and Licensing
Health Technology · Biotechnology · cnyes · 2026-09-04
6657
Taiwan-based Huaan (6657) is set to raise NT$300 million through a new share issuance to fund clinical trials for its F705PD and F703EB drug candidates.
What Happened
Capital Raising: Huaan's board has approved a cash capital increase to issue 10,000 new shares at a tentative price of NT$30 per share, aiming to raise NT$300 million. The proceeds will be used to bolster working capital and accelerate the clinical development of two key drug candidates, strengthening the company's position in international licensing negotiations.
Clinical Pipeline: The Parkinson's disease candidate F705PD has completed Phase I trials and is preparing data for FDA review for Phase II, while the epidermolysis bullosa treatment F703EB is advancing through Phase II trials in Taiwan and the U.S. with orphan drug designations.
Research Milestones: The company's most advanced candidate, F703DFU for diabetic foot ulcers, has submitted interim analysis data to the FDA. Positive results could potentially expedite the regulatory pathway and shorten the time to market for this key product.
Future Outlook: Chairman Chen Han-min expressed optimism for the next two years, noting that the company is entering a harvest period as its core pipeline matures. The firm continues to leverage its proprietary ENERGI cell self-healing platform to target high-value niche markets.